What you should know about the new mRNA flu vaccine
Futurity • • health
Key Points:
- The FDA has approved Moderna’s mFLUSIVA, the first mRNA flu vaccine, for adults aged 50 and older, offering a promising new option to better protect older Americans from influenza.
- Clinical trials showed mFLUSIVA to be about 26.6% more effective than traditional flu vaccines, with a similar safety profile, leading to accelerated FDA approval for this high-risk group.
- Unlike traditional flu vaccines that rely on growing viruses in eggs or isolating proteins, the mRNA platform enables faster production and easier updates to match circulating flu strains, potentially improving vaccine effectiveness each season.
- Availability, pricing, and public demand for the mRNA flu vaccine remain uncertain, and traditional flu shots will still be widely available this season as mRNA vaccines undergo further real-world evaluation.
- The future of flu vaccination may shift depending on real-world effectiveness and uptake of mRNA vaccines, but resistance to mRNA technology could affect how quickly these vaccines replace traditional options.
